Blueprint Investment Partners’s AstraZeneca AZN Stock Holding History

Blueprint Investment Partners’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-4,307	Closed	-$598K	–	150
2023 Q1	$598K	Buy	4,307 +371	+9%	+$49.9K	0.14%	96
2022 Q4	$534K	Buy	3,936 +1,441	+58%	+$181K	0.11%	120
2022 Q3	$274K	Sell	2,495 -438	-15%	-$55.6K	0.07%	107
2022 Q2	$388K	Sell	2,933 -11	-0.4%	-$1.44K	0.1%	95
2022 Q1	$391K	Buy	2,944 +2,003	+213%	+$240K	0.1%	114
2021 Q4	$110K	Buy	941 +107	+13%	+$12.6K	0.03%	230
2021 Q3	$100K	Buy	+834	New	+$97.1K	0.05%	180

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

GQG Partners Ft. Lauderdale, Florida $53.8B AUM 19.23% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Blueprint Investment Partners's AZN Position: Q2 2023 in Review

Blueprint Investment Partners sold out of AstraZeneca (AZN) in Q2 2023, closing a stake of 4,307 shares — an estimated $598K sold.

Blueprint Investment Partners first reported a position in AZN in Q3 2021 and held it in 7 quarters. The position peaked at $598K in Q1 2023. 1,090 funds tracked by Wall St. Rank hold AZN as of Q2 2023.

Blueprint Investment Partners reported no remaining AstraZeneca position as of Q2 2023 after selling out during the quarter.
Blueprint Investment Partners sold 4,307 AstraZeneca shares in Q2 2023, an estimated $598K.
Blueprint Investment Partners first reported a position in AstraZeneca in Q3 2021 and held it in 7 quarters.
Blueprint Investment Partners's AstraZeneca position peaked at $598K in Q1 2023.
1,090 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2023.

Based on Blueprint Investment Partners's 13F filing for Q2 2023, filed 15 Aug 2023.